Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?
Open Access
- 13 June 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (6) , 739
Abstract
The COVID-19 pandemic is associated with a global health crisis and the greatest challenge for scientists and doctors. The virus causes severe acute respiratory syndrome with an outcome that is fatal in more vulnerable populations. Due to the need to find an efficient treatment in a short time, there were several drugs that were repurposed or repositioned for COVID-19. There are many types of available COVID-19 therapies, including antiviral agents (remdesivir, lopinavir/ritonavir, oseltamivir), antibiotics (azithromycin), antiparasitics (chloroquine, hydroxychloroquine, ivermectin), and corticosteroids (dexamethasone). A combination of antivirals with various mechanisms of action may be more efficient. However, the use of some of these medicines can be related to the occurrence of adverse effects. Some promising drug candidates have been found to be ineffective in clinical trials. The knowledge of pharmacogenetic issues, which translate into variability in drug conversion from prodrug into drug, metabolism as well as transport, could help to predict treatment efficiency and the occurrence of adverse effects in patients. However, many drugs used for the treatment of COVID-19 have not undergone pharmacogenetic studies, perhaps as a result of the lack of time.Keywords
This publication has 158 references indexed in Scilit:
- Short Communication: UGT1A1*28 Variant Allele Is a Predictor of Severe Hyperbilirubinemia in HIV-Infected Patients on HAART in Southern BrazilAIDS Research and Human Retroviruses, 2012
- Very important pharmacogene summaryPharmacogenetics and Genomics, 2011
- Atazanavir/Ritonavir-Based Combination Antiretroviral Therapy for Treatment of HIV-1 Infection in AdultsFuture Virology, 2011
- Association of G6PD202A,376G with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemiaBritish Journal of Haematology, 2010
- CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseasesEuropean Journal of Clinical Pharmacology, 2009
- Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug DesignJournal of Virology, 2008
- Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)Annals of the Rheumatic Diseases, 2007
- Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted RatHypertension, 2006
- Down‐regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involvedThe FASEB Journal, 2002
- The Mucosa of the Small IntestineClinical Pharmacokinetics, 2002